Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 9/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5667663 | 0.76 | DYRK1A (0.42) | EGLN2ALDH1A1DYRK1A | |
| SCHEMBL21731043 | 0.73 | EGLN2 (0.38) | EGLN2DYRK1A | |
| SCHEMBL30428953 | 0.68 | ADORA3 (0.44) | ALDH1A1 | |
| SCHEMBL5315895 | 0.68 | KDM4E (0.54) | EGLN2ALDH1A1 | |
| SCHEMBL11003960 | 0.67 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL29781538 | 0.66 | KDM4E (0.52) | EGLN2ALDH1A1DYRK1A | |
| SCHEMBL23055294 | 0.64 | ALDH1A1 (0.42) | EGLN2ALDH1A1 | |
| SCHEMBL29781504 | 0.64 | CSNK1A1 (0.38) | EGLN2 | |
| SCHEMBL3547481 | 0.62 | EGLN2 (0.45) | EGLN2 | |
| SCHEMBL9679567 | 0.62 | DYRK1A (0.44) | EGLN2ALDH1A1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | ADORA2A, ADORA3, ADORA1 | EGLN2 4479/4885NUDT1 75/4885ALDH1A1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.